A phase II open-label study evaluating hemostatic activity, pharmacokinetics and safety of recombinant porcine factor VIII (OBI-1) in hemophilia A patients with alloantibody inhibitors directed against human FVIII

被引：14

作者：

Mahlangu, Johnny ^{[1
]}

Andreeva, Tatiana A. ^{[2
]}

Macfarlane, Donald ^{[3
]}

Reding, Mark T. ^{[4
]}

Walsh, Christopher ^{[5
]}

Ritchie, Bruce ^{[6
]}

Ewing, Nadia ^{[7
]}

Kessler, Craig M. ^{[8
]}

Kempton, Christine ^{[9
]}

Libby, Edward ^{[10
]}

Zozulya, Nadezda ^{[11
]}

Shapiro, Amy D. ^{[12
]}

St-Louis, Jean ^{[13
]}

Warrier, Indira ^{[14
]}

Hoots, W. Keith ^{[15
]}

Gruppo, Ralph A. ^{[16
]}

Mueksch, Josef N. ^{[17
]}

机构：

[1] Johannesburg Hosp, Parktown, South Africa

[2] St Petersburg State Med Inst, St Petersburg, Russia

[3] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA

[4] Univ Minnesota Hosp, Minneapolis, MN USA

[5] Mt Sinai Sch Med, New York, NY USA

[6] Univ Alberta, Edmonton, AB, Canada

[7] City Hope Natl Med Ctr, Duarte, CA USA

[8] Georgetown Univ, Med Ctr, Washington, DC USA

[9] Emory Childrens Ctr, Atlanta, GA USA

[10] Univ New Mexico, Albuquerque, NM 87131 USA

[11] Russian Acad Med Sci, Hematol Res Ctr, Moscow, Russia

[12] Indiana Univ, Hemophilia & Thrombosis Ctr Indiana, Indianapolis, IN USA

[13] Hop Maison Neuve Rosemont, Montreal, PQ, Canada

[14] Childrens Hosp Michigan, Detroit, MI 48201 USA

[15] Gulf States Hemophilia & Thrombophelia Ctr, Houston, TX USA

[16] Cincinnati Childrens Hosp, Cincinnati, OH USA

[17] Octagen Corp, Blue Bell, PA USA

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.783.783

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

783

引用

页码：241A / 241A

页数：1

共 50 条

[21] A phase 1 study of safety and pharmacokinetics (pk) of bax 855, a longer acting pegylated full-length recombinant factor VIII (PEG-RFVIII), in patients (pts) with severe hemophilia A
Bevan, D.
Conlan, M.
Mant, T.
Lissitchkov, T.
Kazmi, R.
Chowdary, P.
Langer, F.
Shima, M.
Fukutake, K.
Singer, J.
Grigorian, A.
Ewenstein, B.
Wong, W. Y.
HAEMOPHILIA, 2013, 19 : 41 - 41
[22] An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, and pharmacokinetics of VIP236 monotherapy in patients with advanced cancer.
Vandross, Andrae L.
Stein, Brian N.
Coward, Jermaine
Sharma, Sunil
Johnson, Amy J.
Birkett, Joseph
Huang, Xin
Frigault, Melanie M.
Lerchen, Hans-Georg
Stelte-Ludwig, Beatrix
Navarro, Tasheda
Peck, Jim
Gross, Wyatt
Izumi, Raquel
Hamdy, Ahmed M.
Rivera, Ildefonso Rodriguez
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[23] Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
Reid, Tony
Oronsky, Bryan
Scicinski, Jan
Scribner, Curt L.
Knox, Susan J.
Ning, Shoucheng
Peehl, Donna M.
Korn, Ron
Stirn, Meaghan
Carter, Corey A.
Oronsky, Arnold
Taylor, Michael J.
Fitch, William L.
Cabrales, Pedro
Kim, Michelle M.
Burris, Howard A.
Lao, Christopher D.
Abrouk, Nacer E. D.
Fanger, Gary R.
Infante, Jeffrey R.
LANCET ONCOLOGY, 2015, 16 (09): : 1133 - 1142
[24] An Open-Label, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Pralatrexate in Relapsed/Refractory Advanced Solid Tumors or Advanced Lymphoma/Myeloma Patients with Mild, Moderate, and Severe Renal Impairment
Kelly, Kevin R.
Gabrail, Nashat Y.
Edenfield, William J.
Lockhart, A. Craig
Olszanski, Anthony J.
Reddy, Guru
BLOOD, 2015, 126 (23)
[25] Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study
Massard, Christophe
Penttinen, Heidi M.
Vjaters, Egils
Bono, Petri
Lietuvietis, Vilnis
Tammela, Teuvo L.
Vuorela, Annamari
Nykanen, Pirjo
Pohjanjousi, Pasi
Snapir, Amir
Fizazi, Karim
EUROPEAN UROLOGY, 2016, 69 (05) : 834 - 840
[26] Achievement of normal factor viii activity following BMN 270 AAV5-FVIII gene transfer: Long-term efficacy and safety from a phase 1/2 study in patients with severe hemophilia A
Pasi, J.
Rangarajan, S.
Kim, B.
Lester, W.
Perry, D.
Madan, B.
Tavakkoli, F.
Yang, K.
Pierce, G.
Wong, W. Y.
HAEMOPHILIA, 2018, 24 : 29 - 29
[27] A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, ±dacarbazine (DTIC) in patients with metastatic melanoma (MM)
Hersey, P
Sosman, J
O'Day, S
Richards, J
Bedikian, A
Gonzalez, R
Sharfman, W
Weber, R
Logan, T
Lawson, D
Zhang, J
Hammershaimb, L
Kirkwood, JM
JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) : 643 - 644
[28] A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM).
Hersey, P
Sosman, J
O'Day, S
Richards, J
Bedikian, A
Gonzalez, R
Sharfman, W
Weber, R
Logan, T
Kirkwood, JM
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 711S - 711S
[29] Phase I/II, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101 (anti-VISTA) as monotherapy and in combination with cemiplimab in patients (pts) with advanced solid tumors
Papadopoulos, K. P.
Call, J. A.
Sen, S.
Smith, D.
van der Horst, E.
ANNALS OF ONCOLOGY, 2023, 34 : S649 - S649
[30] Safety, tolerability, pharmacokinetics, and antitumor activity of FDA022-BB05 in patients with advanced/ metastatic solid tumors: A multicenter, open-label, first-in-human, phase I/Ib study
Wang, X.
Li, Y.
Sun, J.
Sun, Y.
Li, H.
Li, H.
Wang, J.
Ling, X.
Yang, J.
Yan, Y.
Wang, X.
Sun, W.
Liu, K.
ANNALS OF ONCOLOGY, 2024, 35 : S1420 - S1421

← 1 2 3 4 5 →